Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-frequency versus standard-frequency intravesical BCG for high-grade non-muscle invasive bladder cancer
NL-OMON19940Phase 3Recruiting
- Sponsor
- EAU Research Foundation
- Start
- May 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC) and Bladder cancer in situ (CIS) (2 arms), sponsored by EAU Research Foundation. Primary endpoint: Time to first recurrence. Started May 2013; status: recruiting.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on NL-OMON19940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19940.